Copyright
©The Author(s) 2024.
World J Exp Med. Sep 20, 2024; 14(3): 95540
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.95540
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.95540
Table 4 Clinical characteristics of patients according to presence/absence of delayed neurological deterioration and 3-mo outcome after intravenous recombinant tissue plasminogen activator treatment
Variables | Total, n = 418 | No D-ND, n = 182 | D-ND, n = 236 | P value | Good 3-months, n = 250 | Poor 3-months, n = 168 | P value |
Age in yr | 64.5 (53-72) | 60 (49-67.25) | 67 (58-76.75) | < 0.0011 | 60 (50-68) | 69 (61-75) | < 0.0011 |
Sex | |||||||
Male | 249 (59.6) | 120 (65.9) | 129 (54.7) | 0.022 | 162 (64.8) | 87 (51.8) | 0.0082 |
Female | 169 (40.4) | 62 (34.1) | 107 (45.3) | 88 (35.2) | 81 (48.2) | ||
Risk factor | |||||||
Hypertension | 299 (71.5) | 114 (62.6) | 185 (79.1) | < 0.0012 | 163 (65.2) | 136 (81.9) | < 0.0012 |
Dyslipidemia | 276 (66.0) | 113 (62.8) | 163 (69.7) | 0.1412 | 162 (65.3) | 114 (68.7) | 0.4782 |
Diabetes Mellitus | 141 (33.7) | 55 (30.4) | 86 (36.4) | 0.1952 | 73 (29.3) | 68 (40.5) | 0.0182 |
Atrial fibrillation/atrial flutter | 102 (24.4) | 40 (22.0) | 62 (26.3) | 0.3112 | 53 (21.2) | 49 (29.2) | 0.0632 |
Old stroke | 47 (11.2) | 16 (8.8) | 31 (13.2) | 0.162 | 24 (9.7) | 23 (13.7) | 0.212 |
Current smoking | 73 (17.5) | 38 (86.4) | 35 (79.5) | 0.3952 | 52 (85.2) | 21 (77.8) | 0.392 |
Current alcohol drinking | 42 (10.0) | 20 (95.2) | 22 (84.6) | 0.242 | 30 (88.2) | 12 (92.3) | 0.6852 |
Etiology | |||||||
Other determined or undetermined | 177 (42.3) | 69 (38.3) | 108 (46.0) | 0.0042 | 93 (37.5) | 84 (50.3) | 0.0022 |
Cardioembolic | 102 (24.4) | 51 (28.3) | 51 (21.7) | 70 (28.2) | 32 (19.2) | ||
Small-artery occlusion | 94 (22.5) | 50 (27.8) | 44 (18.7) | 66 (26.6) | 28 (16.8) | ||
Large-artery atherosclerosis | 42(10) | 10 (5.6) | 32 (13.6) | 19 (7.7) | 23 (13.8) | ||
Medication | |||||||
Antihypertensive therapy | 202 (45.6) | 81 (44.5) | 121 (51.3) | 0.172 | 111 (44.4) | 91 (54.2) | 0.052 |
Antiplatelet therapy | 81 (18.3) | 31 (17.0) | 50 (21.2) | 0.2872 | 44 (17.6) | 37 (22.0) | 0.2622 |
Hypoglycemic therapy | 121 (27.3) | 53 (29.1) | 68 (28.9) | 0.9672 | 71 (28.5) | 50 (29.8) | 0.7832 |
Infarct volume in mL | 3.27 (0.58-24.24) | 1.16 (0.05-7.88) | 7.61 (1.53-63.41) | 0.361 | 1.46 (0.13-7.93) | 16.62 (2.51-103.09) | 0.0131 |
Time for stroke onset to intravenous rtPA infusion in min | 170.05 (124-218.25) | 182 (0-125) | 167.5 (120-219.5) | 0.5281 | 173.5 (125-218) | 166.5 (120-220) | 0.3061 |
- Citation: Chaiwisitkun A, Muengtaweepongsa S. Platelet-to-neutrophil ratio predicts hemorrhagic transformation and unfavorable outcomes in acute ischemic stroke with intravenous thrombolysis. World J Exp Med 2024; 14(3): 95540
- URL: https://www.wjgnet.com/2220-315x/full/v14/i3/95540.htm
- DOI: https://dx.doi.org/10.5493/wjem.v14.i3.95540